KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Non-Current Assets: 2019-2022

Historic Other Non-Current Assets for Esperion Therapeutics (ESPR) over the last 2 years, with Sep 2022 value amounting to $50.0 million.

  • Esperion Therapeutics' Other Non-Current Assets changed negligibly% to $50.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $50.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $50.0 million for FY2021, which is N/A change from last year.
  • As of Q3 2022, Esperion Therapeutics' Other Non-Current Assets stood at $50.0 million, which was down 0.00% from $50.0 million recorded in Q2 2022.
  • Esperion Therapeutics' Other Non-Current Assets' 5-year high stood at $50.0 million during Q3 2021, with a 5-year trough of $928,000 in Q2 2019.
  • Moreover, its 3-year median value for Other Non-Current Assets was $50.0 million (2022), whereas its average is $36.0 million.
  • Over the last 5 years, Esperion Therapeutics' Other Non-Current Assets had its largest YoY gain of 39.44% in 2020, and its largest YoY loss of 22.21% in 2020.
  • Quarterly analysis of 4 years shows Esperion Therapeutics' Other Non-Current Assets stood at $928,000 in 2019, then spiked by 39.44% to $1.3 million in 2020, then reached $50.0 million in 2021, then remained steady at $50.0 million in 2022.
  • Its last three reported values are $50.0 million in Q3 2022, $50.0 million for Q2 2022, and $50.0 million during Q1 2022.